Pay in 4 interest-free payments of $7.35 Learn more
Ships within 48 hours · Estimated delivery Aug 19 - Aug 24
A: Most patients begin to see weight loss and blood sugar improvements within the first few weeks
Nissen expects tirzepatide to soon join the pure GLP-1 RAs with an FDA-approved indication for weight loss in addition to diabetes, although it may meet the same payer reluctance around reimbursement for weight loss that the pure GLP-1 RAs have
Convenience & Accessibility: Parking: On-site and nearby parking make it easy to visit before or after your day
The starting dose is typically 0.25 mg once weekly, which over time can be steadily increased
Behavioral support improves eating and activity routines between visits
PRODUCT SPECIFICATIONS: Format: 10 lyophilized vials (consistent lot number for study continuity) Strength: 30mg per vial Storage: -20C, protected from light Reconstitution: Bacteriostatic water (not included) COA: Available for each production batch Intended Use: Research Use Only NOT for human consumption RESEARCH APPLICATIONS: GLP-3 receptor activation studies Metabolic regulation pathway research Glucose homeostasis investigation Appetite regulation cascade studies Comparative bioavailability analysis INSTITUTIONAL VALUE PROPOSITION: Consistent lot number across 10 vials ensures experimental reproducibility Cost-effective bulk pricing for labs running extended study protocols Same-day shipping for time-sensitive research timelines Net-30 payment terms available for qualifying institutions QUALITY ASSURANCE: Synthesized in FDA-registered facilities under cGMP protocols Third-party COA verification (purity, endotoxin levels) Full chain-of-custody documentation for audit compliance REGULATORY NOTICE: This product is manufactured and distributed for research purposes only
US$ 20.87
US$ 22.69
US$ 21.33
US$ 26.97
US$ 25.55
